About Enhancer
| Enhancer ID: | E_01098 |
| Species: | Homo sapiens |
| Position : | chr20:48900221-48901229   |
| Year: | 2019 |
| Title: | Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | hepatocellular carcinoma |
| PMID: | 30659195 |
| MONDO: | MONDO:0007256 |
| Tissue: | liver |
| Tissue Ontology ID: | UBERON:0002107 |
| Cell Source: | Hep-G2 |
| CVCL ID: | CVCL_0027 |
| Cell Type: | hepatoblast |
| Cell Ontology ID: | CL:0005026 |
| Experiment Type: | Enhancer activity assay; TF binding assay; Functional perturbation assay; Endogenous enhancer perturbation |
| High Throughput Method: | MBDCap-seq; WGBS; H3K27ac ChIP-seq; H3K4me1 ChIP-seq; H3K4me3 ChIP-seq; H3K27me3 ChIP-seq; CEBPB ChIP-seq; BRD4 ChIP-seq; RNA-seq; whole-genome sequencing |
| Low Throughput Method: | Luciferase reporter assay; CEBPB motif mutagenesis; CRISPR-Cas9 enhancer deletion; dCas9-TET1 targeted enhancer demethylation; ChIP-qPCR; bisulfite pyrosequencing; Northern blot; eRNA RT-qPCR; CEBPB knockdown; JQ1 treatment; Western blot; xenograft assay; CRISPR-Cas9 endogenous deletion/editing |
About Target Gene
| Target gene : | CEBPB |
About TF
| TF name : | CEBPB |
About Regulatory State
| Regulatory State : | Active |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| CEBPB | C-MYB transcription factor network | pid | 87 |
| CEBPB | EGFR1 | netpath | 475 |
| CEBPB | FOXA1 transcription factor network | pid | 45 |
| CEBPB | FOXA2 and FOXA3 transcription factor networks | pid | 45 |
| CEBPB | IFN-gamma pathway | pid | 43 |
| CEBPB | IL3-mediated signaling events | pid | 27 |
| CEBPB | IL4-mediated signaling events | pid | 66 |
| CEBPB | IL4 | netpath | 75 |
| CEBPB | IL6-mediated signaling events | pid | 48 |
| CEBPB | IL6 | netpath | 85 |
| CEBPB | RANKL | netpath | 84 |
| CEBPB | Regulation of nuclear SMAD2/3 signaling | pid | 82 |
| CEBPB | Regulation of retinoblastoma protein | pid | 67 |
| CEBPB | Senescence-Associated Secretory Phenotype (SASP) | reactome | 108 |
| CEBPB | Signaling mediated by p38-alpha and p38-beta | pid | 35 |
| CEBPB | TCR | netpath | 261 |
| CEBPB | Transcriptional regulation of white adipocyte differentiation | reactome | 79 |
| CEBPB | Validated nuclear estrogen receptor alpha network | pid | 65 |
| CEBPB | Hs_Senescence_and_Autophagy_in_Cancer_WP615_81193 | wikipathways | 62 |
| CEBPB | Hs_Oncostatin_M_Signaling_Pathway_WP2374_73668 | wikipathways | 44 |
| CEBPB | Hs_Transcriptional_activation_by_NRF2_WP3_79527 | wikipathways | 6 |
| CEBPB | Hs_Lung_fibrosis_WP3624_91475 | wikipathways | 23 |
| CEBPB | Hs_IL17_signaling_pathway_WP2112_89838 | wikipathways | 20 |
Enhancer Associated Network
Overlapping Enhancers (hg19)
10 found
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_02876 | chr20:48400000-49200000 | breast | malignant cell | breast cancer |
| E_02877 | chr20:48400000-49200000 | breast | malignant cell | breast cancer |
| E_01105 | chr20:48900221-48901229 | liver | NA | hepatocellular carcinoma |
| E_01106 | chr20:48900221-48901229 | liver | NA | hepatocellular carcinoma |
| E_01107 | chr20:48900221-48901229 | liver | malignant cell | hepatocellular carcinoma |
| E_01108 | chr20:48900221-48901229 | liver | hepatocyte | hepatocellular carcinoma |
| E_01115 | chr20:48900221-48901229 | liver | NA | hepatocellular carcinoma |
| E_01116 | chr20:48900221-48901229 | liver | NA | hepatocellular carcinoma |
| E_01143 | chr20:48900221-48901229 | uterine cervix | NA | hepatocellular carcinoma |
| E_01145 | chr20:48900221-48901229 | liver | NA | hepatocellular carcinoma |
Expression of Target Genes for the Enhancer